| Axi-cel in CNS Lymphoma (NCT04608487) | Dana-Farber Cancer Institute | 2020-12-04 |
| Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients (NCT04604158) | Gillian Gresham | 2020-12-02 |
| National Longitudinal Cohort of Hematological Diseases (NCT04645199) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-01 |
| Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²) (NCT04320420) | Weprom | 2020-11-20 |
| A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas (NCT04464798) | Celgene | 2020-11-11 |
| Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors (NCT04472286) | University of Nebraska | 2020-11-01 |
| Tempus Priority Study: A Pan-tumor Observational Study (NCT05179824) | Tempus AI | 2020-10-19 |
| Tumor Molecular Profiling in Early Phase Clinical Trials (NCT04510766) | Oncology Institute of Southern Switzerland | 2020-10-01 |
| Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) (NCT04434937) | Incyte Biosciences Japan GK | 2020-09-30 |
| Supportive Oncology Care At Home RCT (NCT04544046) | Massachusetts General Hospital | 2020-09-16 |
| Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial (NCT04190433) | Mayo Clinic | 2020-09-01 |
| Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas (NCT04407741) | Chinese PLA General Hospital | 2020-09-01 |
| Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases (NCT04504526) | First Affiliated Hospital of Fujian Medical University | 2020-08-07 |
| Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel (NCT04514029) | Masonic Cancer Center, University of Minnesota | 2020-08-06 |
| Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies (NCT04497701) | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 2020-08-01 |
| Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children (NCT04610125) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-06-23 |
| CAR-37 T Cells in Hematologic Malignancies (NCT04136275) | Marcela V. Maus, M.D.,Ph.D. | 2020-06-19 |
| Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors (NCT04169321) | Cytosite Biopharma Inc. | 2020-06-16 |
| A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas (NCT04306224) | ImmuneOncia Therapeutics Inc. | 2020-06-05 |
| An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NCT04186637) | Alpine Immune Sciences, Inc. | 2020-06-02 |
| Effects of Periodized and Autoregulated Resistance Training in Haematological Cancer Patients During the Treatent. (NCT04406285) | Federal University of Health Science of Porto Alegre | 2020-06-01 |
| Home Hospital for Lymphoma (NCT04423848) | Massachusetts General Hospital | 2020-06-01 |
| Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma (NCT04478318) | University of California, Davis | 2020-06-01 |
| Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1) (NCT04386512) | Versailles Hospital | 2020-05-15 |
| Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia (NCT04349306) | Sanofi | 2020-05-14 |
| Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma (NCT04367948) | Peking University Cancer Hospital & Institute | 2020-05-01 |
| Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL (NCT04342117) | SecuraBio | 2020-04-23 |
| Precision Medicine for Patients With Identified Actionable Mutations (NCT04111107) | Wake Forest University Health Sciences | 2020-04-22 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations (NCT04094610) | Turning Point Therapeutics, Inc. | 2020-03-12 |
| Study of CAR-T Therapy in Older Patients (NCT04300998) | Memorial Sloan Kettering Cancer Center | 2020-03-04 |
| Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04496011) | Federal University of Health Science of Porto Alegre | 2020-03-02 |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 (NCT04144140) | Eisai Inc. | 2020-02-24 |
| Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study (NCT04081779) | Fred Hutchinson Cancer Center | 2020-02-19 |
| Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL (NCT04163575) | Kecellitics Biotech Company Ltd | 2020-02-01 |
| CMP-001 for Relapsed and Refractory Lymphoma (NCT03983668) | Umar Farooq | 2020-01-31 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (NCT03934372) | Incyte Biosciences International Sàrl | 2020-01-29 |
| Quality of Life in Lymphoma Patients One Year Post-chemotherapy (NCT04187118) | University Hospital, Toulouse | 2020-01-28 |
| Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions (NCT04132843) | M.D. Anderson Cancer Center | 2020-01-10 |
| CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (NCT04088864) | Kara Lynn Davis | 2020-01-10 |
| Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies (NCT05011045) | M.D. Anderson Cancer Center | 2020-01-09 |
| Better Leukemia Diagnostics Through AI (BELUGA) (NCT04466059) | Munich Leukemia Laboratory | 2020-01-05 |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors (NCT04214093) | AstraZeneca | 2019-12-16 |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy (NCT04014764) | Notable Labs | 2019-12-15 |
| Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants (NCT04167137) | Synlogic | 2019-12-12 |
| Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI (NCT04154228) | Tel-Aviv Sourasky Medical Center | 2019-12-10 |
| Effect of Vitamin C in Autologous Stem Cell Transplantations (NCT03964688) | Maastricht University Medical Center | 2019-12-10 |
| EFFECT OF A 16-SESSION QIGONG PROGRAM ON PHYSICAL AND MENTAL HEALTH IN PATIENTS WITH LYMPHOMA: A RANDOMIZED CONTROLLED TRIAL (NCT04701554) | Consuelo Lourdes Díaz Rodríguez | 2019-12-01 |
| Applying PET/MR in Oncology - a Prospective Project (NCT04158414) | Tel-Aviv Sourasky Medical Center | 2019-11-28 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation (NCT03856216) | M.D. Anderson Cancer Center | 2019-10-28 |
| Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation (NCT03836690) | University College, London | 2019-10-21 |
| Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease (NCT04039100) | Rigshospitalet, Denmark | 2019-10-01 |
| Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (NCT03936465) | Dana-Farber Cancer Institute | 2019-09-27 |
| QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (NCT04052061) | ImmunityBio, Inc. | 2019-09-16 |
| Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma (NCT04270266) | M.D. Anderson Cancer Center | 2019-09-06 |
| Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) (NCT03990961) | University of Chicago | 2019-09-04 |
| Diffusion-weighted Magnetic Resonance Imaging in Post Therapy Patients With Lymphoma (NCT03969381) | Assiut University | 2019-09-01 |
| Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma (NCT03919175) | Massachusetts General Hospital | 2019-09-01 |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma (NCT03995147) | University of Chicago | 2019-08-29 |
| Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas (NCT03786926) | Hutchmed | 2019-08-26 |
| Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications (NCT04053439) | Sunnybrook Health Sciences Centre | 2019-08-08 |
| Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza) (NCT04119154) | Harvard School of Public Health (HSPH) | 2019-08-01 |
| A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin (NCT04069845) | Ruijin Hospital | 2019-08-01 |
| Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma (NCT03921879) | Oncotartis, Inc. | 2019-07-29 |
| Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia (NCT04037189) | Rabin Medical Center | 2019-07-28 |
| Cardiovascular Effects of CART Cell Therapy (NCT04026737) | Abramson Cancer Center at Penn Medicine | 2019-07-22 |
| Rehabilitation Needs of the Malaysian Haematological Cancer Survivors (NCT04236063) | University of Malaya | 2019-07-15 |
| TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) (NCT03959241) | Medical College of Wisconsin | 2019-06-25 |
| Spa Therapy for Upper or Lower Limb Lymphoedema (NCT03580109) | Association Francaise pour la Recherche Thermale | 2019-06-20 |
| A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma (NCT03829254) | NuCana plc | 2019-06-17 |
| ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma (NCT04014894) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-06-12 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| Self-Management and Activation to Reduce Treatment-Related Toxicities (SMARTCare) (NCT03849950) | University Health Network, Toronto | 2019-06-11 |
| Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma (NCT03436342) | Peking Union Medical College Hospital | 2019-06-01 |
| A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma (NCT03834584) | Agios Pharmaceuticals, Inc. | 2019-05-24 |
| Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours (NCT03852823) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2019-05-23 |
| Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx (NCT03923504) | Virginia Commonwealth University | 2019-05-10 |
| Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study (NCT03850171) | Insel Gruppe AG, University Hospital Bern | 2019-05-01 |
| MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma (NCT03932955) | Peking University | 2019-05-01 |
| HeartPhone Cancer Survivors Trial 2019 (NCT03953326) | Penn State University | 2019-04-23 |
| Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma (NCT03934814) | I-Mab Biopharma US Limited | 2019-04-16 |
| TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers (NCT03884556) | Trishula Therapeutics, Inc. | 2019-04-10 |
| PROactive Evaluation of Function to Avoid CardioToxicity (NCT03862131) | Washington University School of Medicine | 2019-03-13 |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (NCT03696784) | UNC Lineberger Comprehensive Cancer Center | 2019-03-12 |
| Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (NCT03586024) | Abramson Cancer Center at Penn Medicine | 2019-03-12 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (NCT03775525) | Genzada Pharmaceuticals USA, Inc. | 2019-03-01 |
| Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database (NCT04074213) | University Hospital, Caen | 2019-03-01 |
| Post-Op Pain Control for Prophylactic Intramedullary Nailing. (NCT03823534) | St. Louis University | 2019-02-20 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma (NCT04263935) | Henan Cancer Hospital | 2019-01-03 |
| Effect of Needle Size in Diagnostic Yield of EBUS-TBNA in Sarcoidosis and Lymphoma (NCT03573362) | Centre hospitalier de l'Université de Montréal (CHUM) | 2019-01-01 |
| A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations (NCT03793140) | Memorial Sloan Kettering Cancer Center | 2018-12-31 |
| An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer (NCT03794635) | Memorial Sloan Kettering Cancer Center | 2018-12-20 |
| KN046 in Subjects With Advanced Solid Tumors and Lymphoma (NCT03733951) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2018-12-18 |
| A Study of Isatuximab-based Therapy in Participants With Lymphoma (NCT03769181) | Sanofi | 2018-12-11 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676) | Juno Therapeutics, a Subsidiary of Celgene | 2018-11-29 |
| Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue (NCT03747757) | M.D. Anderson Cancer Center | 2018-11-29 |
| CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (NCT03684889) | Seattle Children's Hospital | 2018-11-28 |
| CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig (NCT03383055) | Masonic Cancer Center, University of Minnesota | 2018-11-16 |
| Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies (NCT03722186) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-13 |
| A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas (NCT03991559) | Chinese PLA General Hospital | 2018-11-01 |